The beneficial effect of (-)-epigallocatechin-3-gallate in an experimental model of Alzheimer's disease in rat: A behavioral analysis

Iranian Biomedical Journal

Volumn 11, Issue 4, 2007, Pages 237-243

  Rasoolijazi, Homa ^a   Joghataie, Mohammad Taghi ^a   Roghani, Mehrdad ^b   Nobakht, Maliheh ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

Author keywords

Alzheimer's disease (AD); Behavior; Epigallocatechin gallate (EGCG); Hippocampus

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; ANTIOXIDANT; EPIGALLOCATECHIN GALLATE;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIOR DISORDER; COGNITION; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPUS; MALE; MAZE TEST; NONHUMAN; RAT;

ALZHEIMER DISEASE; ANIMALS; CATECHIN; DISEASE MODELS, ANIMAL; MALE; MAZE LEARNING; PSYCHOMOTOR PERFORMANCE; RATS; RATS, WISTAR;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 35648943213     PISSN: 1028852X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K. and Minthon, L. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5: 228-234.
2. Tiraboschi, P., Hansen, L.A., Thal, L.J. and Coreybloom, J. (2004) The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62: 1984-1989.
3. Holroyd, S. and Shepherd, M.L. (2001) Alzheimer's Disease: A Review for the ophthalmologist. Surv. Ophthalmol. 45 (6): 516-524.
4. Maccioni, R.B., Muñoz, J.P. and Barbeito, L. (2001) The Molecular Bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 32: 367-381.
5. Banks, W.A. and Farr, S.A. (2004) Antiaging methods and medicines for the memory. Clin. Geriatr. Med. 20: 317-328.
6. Vagnucci Jr, A.H. and Li, W.W. (2003) Alzheimer's disease and angiogenesis. Lancet 361: 605-608.
7. Richwine, A.F., Godbout, J.P., Berg, B.M., Chen, J., Escobar, J., Millard, D.K. and Johnson, R.W. (2005) Improved psychomotor performance in aged mice fed diet high in antioxidants is associated with reduced ex vivo brain interleukin-6 production. Brain Behav. Immun. 19: 512-520.
8. Miguel-Hidalgo, J.J., Alvarez, X.A., Cacabelos, R. and Quack, G. (2002) Neuroprotection by memantine against neurodegeneration induced by β-amyloid (1-40). Brain Res. 958: 210-221.
9. Mcdonald, M.P. and Overmier J.B. (1998) Present imperfect: A critical review of animal models of mnemonic impairments in Alzheimer's disease. Neurosci. Biobehav. Rev. 22 (1): 99-12.
10. Skrzypczak-Jankun, E., Zhou, K. and Jankun, J. (2003) Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 Å reveals degradation of EGCG and shows soybean LOX-3 complex with EGC instead. Int. J. Mol. Med. 12: 415-422.
11. Tosetti, F., Ferrari, N., De Flora, S. and Albini, A. (2002) 'Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 16: 2-14.
12. Song, X.Z., Bi, Z.G. and Xu, A.E. (2006) Green tea polyphenol epigallocatechin-3-gallate inhibits the expression of nitric oxide synthase and generation of nitric oxide induced by ultraviolet B in HaCaT cells. Chin. Med. J. (Engl.) 119 (4): 282-287.
13. Roghani, M., Joghataie, M.T., Jalali, M.R. and Baluchnejadmojarad T. (2006) Time Course of Changes in Passive Avoidance and Y-maze Performance in Male Diabetic Rats. Iran. Biomed. J. 10 (2): 99-104.
14. Ding, Y., Li, J., Lia, Q., Rafols, J.A., Luan, X., Clark, J. and Diaz, F.G. (2004) Motor balance and coordination training enhances functional outcome in rat with transient middle cerebral artery occlusion. Neuroscience 123 (3): 667-674.
15. Shukitt-Hale, B., Mouzakis, G. and Joseph, J.A. (1998) Psychomotor and spatial memory performance in aging male Fischer 344 rats. Exp. Gerontol. 33 (6): 615-624.
16. Lu, Y.P., Zeng, M., Hu, X.Y., Xu, H., Swaab, D.F., Ravid, R. and Zhou, J.N. (2003) Estrogen receptor α-immunoreactive astrocytes are increased in the hippocampus in Alzheimer's disease. Exp. Neurol. 183: 482-488.
17. Holland, P.C., Lamoureux, J.A., Han, J.S. and Gallagher, M. (1999) Hippocampal lesions interfere with pavlovian negative occasion setting. Hippocampus 9: 143-157.
18. Deacon, R.M.J., Croucher, A. and Rawlins, J.N.P. (2002) Hippocampal cytotoxic lesion effects on species-typical behaviours in mice. Behav. Brain Res. 132: 203-213.
19. Malin, D.H., Crothers, M.K., Lake, J.R., Goyarzu, P., Plotner, R.E., Garcia S.A., Spell, S.H., Tomsic, B.J., Giordano, T. and Kowall N.W. (2001) Hippocampal injections of amyloid β-peptide 1-40 impair subsequent one-trial/day reward learning. Neurobiol. Learn Mem. 76(2): 125-137.
20. Stephan, A., Laroche, S. and Davis, S. (2001) Generation of aggregated β-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J. Neurosci. 21 (15): 5703-5714.
21. Koudinov, A.R., Berezov, T.T. and Koudinova, N.V. (2001) Amyloid plaque (and not diffuse amyloid) is a condition for neuronal dysfunction. Clin. Med. Health Res :9-16.clinmed/2001110002.
22. Hashimoto, M., Hossain, S., Shimada, T., Sugioka, K., Yamasaki, H., Fujii, Y., Ishibashi, Y., Oka, J. and Shido, O. (2002) Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J. Neurochem. 81(5): 1084-1091.
23. Skutella, T. and Nitsch, R. (2001) New molecules for hippocampal development. Trends Neurosci. 24 (2): 107-113.
24. Basini, G., Bianco, F. and Grasselli, F. (2005) Epigallocatechin-3- gallate from green tea negatively affects swine granulosa cell function. Domest. Anim. Endocrinol. 28: 243-256.
25. 2+/calmodulin-dependent protein kinase ??, and redox state are involved in epigallocatechin gallate-induced phospholipase D activation in human astroglioma cells. Eur. J. Biochem. 271: 3470-3480.
26. Levites, Y., Amit, T., Mandel, S. and Toudim, M.B. (2003) Neuroprotection and neurorescue against Aβ toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. 17 (8): 952-954.
27. Choi, Y.T., Jung, C.H., Lee, S.R., Bae, J.H., Baek, W.K., Suh, M.H., Park, J., Park, C.W. and Suh, S.I. (2001) The green tea polyphenol (-)-epigallocatechin gallate attenuates β-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci. 70: 603-614.
28. Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Townsend, K., Zeng, J., Morgan, D., Hardy, J., Town, T. and Tan J. (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reducea cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25 (38): 8807-8814.
29. Haque, A.M., Hishimoto, M., Katakura, M., Tanabe, Y., Hara, Y. and Shido, O. (2006) Long-term administration of green tea catechins improves spatial cognition learning ability in rats. J. Nutr. 136: 1043-1047.